🌍·9h agodiscovery
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Publisher
T
The Manila Times
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- The Manila Times
- Region
- Global
- Scope
- discovery
- Published
- June 26, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: The Manila Times
Scope: discovery
Related coverage
More related coverage
BioPharma Dive/4h ago
At BIO, tension over China biotech deal regulation looms
Investing.com/4h ago
UBS raises Incyte stock price target to $113 on biotech recovery
PharmTech.com/4h ago
Thermo Fisher's Kane Says AI Is Reshaping How CDMOs Add Value
TradingView/4h ago